CD19 and plasma cell myeloma: We consider the development strategies of dual-targeting CD19/CD20 [157], CD19/CD22 [158], and BCMA/CD38 CAR-T cells [159] in preclinical models and clinical trials of hematologic malignancies and multiple myeloma.